炎症性肠病的新兴疗法:全面审查
John K Appiah1, Umar Hayat1, Nikita Garg1
1Department of Internal Medicine, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA 18711, USA.
Journal of clinical medicine
|September 13, 2025
概括
对于炎症性肠病 (IBD) 的新兴疗法,包括新的生物药物和基于细胞的治疗方法,为患者提供了新的希望. 本综述强调了它们的机制,有效性和安全性,指导了未来的IBD管理策略.
科学领域:
- 胃肠道学和免疫学
- 药物发现和开发 药物发现和开发
- 再生医学是一种再生医学.
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),带来了慢性挑战,影响了患者的生活质量.
- 目前的IBD治疗方法,包括生物药物,面临部分疗效,副作用和耐药性等局限性,需要新的治疗策略.
研究的目的:
- 审查和总结IBD管理的新兴治疗方法.
- 探索新的生物药物,小分子,基于微生物组的疗法,基因疗法和IBD的干细胞疗法.
主要方法:
- 一个全面的叙事综述,综合了最近 (2020-2024) 的高质量的文学作品.
- 文献搜索包括随机对照试验,系统评论,元分析,监管文件和临床指南.
- 专注于FDA / EMA批准和IBD的晚期研究药物.
主要成果:
- 新兴疗法包括新生物,小分子,基于微生物的干预措施,基因疗法和干细胞治疗.
- 这些新的方法针对特定的免疫路径,并提供了提高疗效和安全性概况的潜力.
- 该审查详细介绍了这些先进IBD疗法的作用机制,临床疗效和安全数据.
结论:
- 创新疗法正在扩大IBD的治疗领域,解决当前治疗方法的局限性.
- 未来的IBD管理可能会整合这些新的方法,包括生物制剂,小分子和基于细胞的疗法.
- 持续的研究和临床试验对于优化这些新兴治疗方法在IBD护理中的使用至关重要.
更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
644
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439


